About

Dr. Zhigang Ji is a pioneering urologic surgeon and researcher at the forefront of robotic surgery innovation, with a primary focus on developing and validating next-generation surgical robotic systems. His most significant contributions center on the clinical translation of the KangDuo Surgical Robot (KD-SR), a domestically developed Chinese robotic platform designed to compete with the established da Vinci system. In a landmark double-center prospective randomized controlled noninferiority trial (2022, 54 citations), Dr. Ji demonstrated that the KD-SR is as safe and effective as the da Vinci Si for robot-assisted partial nephrectomy, a critical step toward reducing surgical costs and expanding access. He further advanced the field by proving the feasibility of dual-console telesurgery using 5G and wired networks (2023, 26 citations), a breakthrough with profound implications for remote surgical care, especially highlighted during the COVID-19 pandemic. Dr. Ji has also established the safety and efficacy of the KD-SR-01 system for partial adrenalectomy (2023, 15 citations) and radical prostatectomy (2024, 8 citations), systematically expanding the platform’s applications. His work is not only technically rigorous but also addresses pressing global needs for affordable, high-quality surgical technology.

Research Focus

Key Achievements

5
H-Index
6
Papers
123
Total Citations
21
Avg Citations/Paper
🏆 Most Cited Paper
Robot-assisted Partial Nephrectomy with the Newly Developed KangDuo Surgical Robot Versus the da Vinci Si Surgical System: A Double-center Prospective Randomized Controlled Noninferiority Trial
54 citations · 2022
📈 Most Prolific Year: 2022 (2 Papers)
🤝 Key Collaborators: 29
🏛 Institutions: Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College

Top Papers

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 14 days ago